Evidence map›Paper›PMID 39355570›Full record

ReviewDrug design, development and therapy2024

Dauricine: Review of Pharmacological Activity.

Ke-Qian Chen, Shu-Zhi Wang, Hai-Bo Lei, Xiang Liu

Abstract readReview
In one paragraph

Review in Drug design, development and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ke-Qian Chen *Department of Clinical Pharmacy, Xiangtan Central Hospital, Xiangtan, 411100, People's Republic of China.
Shu-Zhi Wang *Institute of Pharmacy and Pharmacology, School of Pharmaceutical Sciences, Hengyang Medical School, University of South China, Hengyang, 421001, People's Republic of China.
Hai-Bo LeiDepartment of Clinical Pharmacy, Xiangtan Central Hospital, Xiangtan, 411100, People's Republic of China.
Xiang LiuDepartment of Clinical Pharmacy, Xiangtan Central Hospital, Xiangtan, 411100, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Dauricine is an important natural organic compound in Purpose: The purpose of this review is to systemically summarize and discuss the pharmacological activity and underlying mechanisms of dauricine in recent years. Methods: Web of Science (121 articles) and PubMed databases (97 articles) were used to search for articles related to "dauricine" published from 2000 to 2024. Meanwhile, we classified the pharmacological activity of dauricine by screening these articles. Results: Emerging evidence suggests that dauricine possesses numerous pharmacological activities, including neuroprotection, anti-cancer, anti-arrhythmia, anti-inflammatory and anti-diabetes. Conclusion: Dauricine has a potential value in the treatment of many diseases. We hope that this review will contribute to therapeutic development and future studies of dauricine.

Indexed as

BenzylisoquinolinesTetrahydroisoquinolinesAnimalsAnti-Arrhythmia AgentsAnti-Inflammatory AgentsAntineoplastic AgentsHumansHypoglycemic AgentsNeuroprotective AgentsAnti-Arrhythmia AgentsAnti-Inflammatory AgentsAntineoplastic AgentsBenzylisoquinolinesdauricineHypoglycemic AgentsNeuroprotective AgentsTetrahydroisoquinolinesdauricinemenispermum dauricumpharmacokineticspharmacologytoxicity

Identifiers

PMID39355570
PMCPMC11444063

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.